Retroscreen Virology Group, which creates drugs and vaccines for a number of viral respiratory diseases, has signed a Viral Challenge Model contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study.

The contract, valued at £5.9m, will be the largest RSV challenge study conducted by Retroscreen to-date.

Kym Denny, Chief Executive Officer, said: "We are delighted to be working with such an innovative pharmaceutical company on the development of their novel product.

"This contract win comes from the building momentum of Retroscreen's sales pipeline and highlights the pharmaceutical industry's increasing awareness of the benefits of the VCM in accelerating drug development and product decision-making."

NR

Related share prices
Retroscreen Virology Group (RVG) share price